Business Description
Opthea Ltd
ISIN : AU000000OPT2
Total Employee Number:
10Description
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.3 | |||||
Equity-to-Asset | -3.54 | |||||
Debt-to-Equity | -0.8 | |||||
Debt-to-EBITDA | -1.28 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -29.68 | |||||
Beneish M-Score | -6.13 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 27.2 | |||||
3-Year EPS without NRI Growth Rate | 14 | |||||
3-Year FCF Growth Rate | 11.7 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 852.38 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.22 | |||||
Quick Ratio | 0.22 | |||||
Cash Ratio | 0.19 | |||||
Days Sales Outstanding | 17857.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -44.8 | |||||
Shareholder Yield % | -1096.51 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -594040 | |||||
Net Margin % | -639297.5 | |||||
EBITDA Margin % | -485487.5 | |||||
FCF Margin % | -634628 | |||||
OCF Margin % | -634576 | |||||
ROA % | -127.49 | |||||
ROIC % | -131.18 | |||||
3-Year ROIIC % | -25.5 | |||||
ROC (Joel Greenblatt) % | -116601 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio without NRI | 0.62 | |||||
EV-to-EBIT | -0.28 | |||||
EV-to-EBITDA | -0.28 | |||||
EV-to-Revenue | 1362.93 | |||||
EV-to-Forward-Revenue | 5186.55 | |||||
EV-to-FCF | -0.22 | |||||
Earnings Yield (Greenblatt) % | -357.14 | |||||
FCF Yield % | -1387.87 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CKDXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Opthea Ltd Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.025 | ||
| EPS (TTM) ($) | -0.133 | ||
| Beta | -1.7038 | ||
| 3-Year Sharpe Ratio | -0.15 | ||
| 3-Year Sortino Ratio | -0.25 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | 0.01172 | ||
| 20-Day SMA ($) | 0.139 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.01 - 0.44 | ||
| Shares Outstanding (Mil) | 1,367.98 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Opthea Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Opthea Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2026-09-15 | In 79 days | ||
| Fourth quarter earnings results for 2026 | 2026-08-28 | In 61 days | ||
| Second quarter earnings results for 2026 | 2026-03-02 | 0.44 (+0.00%) | ||
| Annual report for 2025 | 2025-09-15 | 0.44 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-08-29 | 0.44 (+0.00%) | ||
| Oppenheimer’s 35th Annual Healthcare Life Sciences Conference | 2025-02-11 10:00 | 0.44 (+0.00%) | ||
| Opthea Investor Day | 2025-02-05 16:30 | 0.44 (+0.00%) | ||
| Opthea Investor Day | 2025-02-03 16:30 | 0.44 (+0.00%) | ||
| 43rd Annual J.P. Morgan Healthcare Conference | 2025-01-15 17:15 | 0.44 (+0.00%) | ||
| Guidance call for 2024 | 2024-12-05 13:45 | 0.44 (+0.00%) |
Show
Entries
Opthea Ltd Frequently Asked Questions
What is Opthea Ltd(CKDXF)'s stock price today?
The current price of CKDXF is $0.01. The 52 week high of CKDXF is $0.44 and 52 week low is $0.01.
When is next earnings date of Opthea Ltd(CKDXF)?
The next earnings date of Opthea Ltd(CKDXF) is 2026-08-28 Est..
Does Opthea Ltd(CKDXF) pay dividends? If so, how much?
Opthea Ltd(CKDXF) does not pay dividend.
Guru Commentaries on OTCPK:CKDXF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Opthea Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers